{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-126446","form_type":"8-K","ticker":"MRKR","cik":"0001094038","company_name":"Marker Therapeutics, Inc.","filed_at":"2022-12-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.588476+00:00","generated_at":"2026-06-21T05:10:44.129285+00:00","sec_items":["1.01","3.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Marker Therapeutics enters $25M common stock purchase agreement with Lincoln Park Capital","bullets":["Up to $25M in common stock may be sold to Lincoln Park over 24 months at Marker's discretion.","Pricing based on prevailing market prices; no upper limit per share and no warrants issued.","Marker issued 1,804,098 commitment shares to Lincoln Park as consideration.","Lincoln Park covenants not to engage in short selling or hedging of Marker's stock.","Proceeds to fund Phase 2 ARTEMIS trial, lymphoma/pancreatic programs, and working capital."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-126446","json":"https://secwatch.observer/filing/0001104659-22-126446.json","markdown":"https://secwatch.observer/filing/0001104659-22-126446.md","text":"https://secwatch.observer/filing/0001104659-22-126446.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1094038/000110465922126446/0001104659-22-126446-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1094038/000110465922126446/tm2232522d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T05:10:44.129285+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"28da93f720940c888f633ecfd0b9669fa18b4a04","claim":"Marker Therapeutics, Inc. entered into Purchase Agreement with Lincoln Park Capital Fund, LLC valued at up to $25,000,000 of shares of our common stock (effective 2022-12-12).","evidence_excerpt":"On December 12, 2022, Marker Therapeutics, Inc., a Delaware corporation referred to herein as we, us, our or the Company, entered into a purchase agreement, or the Purchase Agreement, with Lincoln Park Capital Fund, LLC, or Lincoln Park, which provides that, upon the terms and subject to the conditions and limitations set forth therein, we have the right, but not the obligation, to sell to Lincoln Park up to $25,000,000 of shares of our common stock, or the Purchase Shares, from time to time over the 24-month term beginning on the Commencement Date (as defined below).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1094038/000110465922126446/0001104659-22-126446-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"Lincoln Park Capital Fund, LLC"},{"label":"Value","value":"up to $25,000,000 of shares of our common stock"},{"label":"Effective","value":"2022-12-12"}],"fact_type":"material_agreement"},{"claim_id":"6d5579e637b503a423d7240dd0d337aa52b83cdc","claim":"Marker Therapeutics, Inc. entered into Registration Rights Agreement with Lincoln Park Capital Fund, LLC (effective 2022-12-12).","evidence_excerpt":"Concurrently with entering into the Purchase Agreement, we also entered into a registration rights agreement with Lincoln Park, or the Registration Rights Agreement, pursuant to which we agreed to register the sale of the shares of our common stock that have been and may be issued to Lincoln Park under the Purchase Agreement pursuant to a Registration Statement on Form S-1, or the Registration Statement.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1094038/000110465922126446/0001104659-22-126446-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"Lincoln Park Capital Fund, LLC"},{"label":"Effective","value":"2022-12-12"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}